300 One Kendall Square, 3rd Floor, Cambridge, MA 02139.
Gemini Therapeutics is incorporated in Delaware.
Gemini Therapeutics was founded in 2015.
Gemini Therapeutics’ shares are traded on the Nasdaq Global Select Market under the symbol “GMTX”.
Gemini went public via merger with FS Development Corp. (FSDC), a special purpose acquisition company (SPAC), on February 8, 2021.
Gemini Therapeutics’ fiscal year ends on December 31.
Ernst & Young
36870G105
Shares of Gemini Therapeutics’ stock can be purchased by contacting a securities broker of your choice.
No. Gemini does not have a direct stock purchase plan. You may purchase shares of Gemini through a broker of your choice.
Gemini Therapeutics does not pay dividends at this time.
Continental Stock Transfer & Trust Live Call support: 212-509-4000 e-mail: [email protected] Online Contact: https://continentalstock.com/contact/
If you have misplaced your share certificates, please contact Gemini Therapeutics’ transfer agent, Continental Stock Transfer & Trust, via the information provided above.
If the shares are held in your name, you must contact Gemini Therapeutics’ transfer agent, Continental Stock Transfer & Trust, via the information provided above. If your shares are held in street name, you must contact your broker to update your address.
Quarterly & Annual reports and other investor materials are available in the “Investors” section of Gemini Therapeutics’ corporate website. Additionally, all SEC filings can also be accessed directly from the SEC at www.sec.gov.
Please click here to be directed to the email alerts page.
For media and investor inquiries, please send an email to [email protected].